Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | AR | P10275 | 12/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089591 | 0.81 | PARP1 (0.62) | TSHRARPARP1LMNACYP3A4 | |
| SCHEMBL4088774 | 0.79 | TSHR (0.68) | TSHRARPARP1LMNAHTT | |
| SCHEMBL12798218 | 0.79 | TSHR (0.68) | TSHRARPARP1LMNAHTT | |
| SCHEMBL3353081 | 0.78 | TSHR (0.64) | TSHRARPARP1LMNAHTT | |
| SCHEMBL3353503 | 0.76 | TSHR (0.64) | TSHRARPARP1LMNA | |
| SCHEMBL12798214 | 0.75 | TSHR (0.62) | TSHRARPARP1LMNAHTT | |
| SCHEMBL6606293 | 0.73 | TSHR (0.72) | TSHRARPARP1LMNAPRMT5 | |
| SCHEMBL3635493 | 0.71 | LMNA (0.56) | TSHRARPARP1LMNACYP3A4 | |
| SCHEMBL6788051 | 0.69 | ATM (0.58) | TSHRLMNANPSR1POLBPRMT5 | |
| SCHEMBL3350841 | 0.69 | PARP1 (0.73) | TSHRPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| EP-1948642-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Ltd (GB) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | TSHR 725/4885AR 96/4885PARP1 2875/4885 |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | TSHR 775/4885AR 80/4885PARP1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.